跳到主要导航 跳到搜索 跳到主要内容

Pressure-induced amorphous zeolitic imidazole frameworks with reduced toxicity and increased tumor accumulation improves therapeutic efficacy In vivo

  • Zhenqi Jiang
  • , Yanying Li
  • , Zhenni Wei
  • , Bo Yuan
  • , Yinjie Wang
  • , Ozioma Udochukwu Akakuru
  • , Yong Li
  • , Juan Li*
  • , Aiguo Wu*
  • *此作品的通讯作者
  • CAS - Ningbo Institute of Material Technology and Engineering
  • University of Chinese Academy of Sciences

科研成果: 期刊稿件文章同行评审

摘要

Zeolitic Imidazole Frameworks (ZIFs) are widely applied in nanomedicine for their high drug loading, suitable pore size, pH-responsive drug release, and so on. However, fast drug release during circulation, unexpected toxicity to mice major organs, undesirable long-term accumulation in the lung and even death currently hinder their in vivo biomedical applications. Herein, we report an amorphous ZIF-8 (aZIF-8) with high loading of 5-Fu through pressure-induced amorphization. This nano-system avoids early drug release during circulation and provides tumor microenvironment-responsive drug release with improved in vitro cell viability, and survival rate in in vivo evaluations as compared to ZIF-8. Furthermore, aZIF-8 shows longer blood circulation and lower lung accumulation than ZIF-8 at same injected doses. Less drug release during circulation, longer blood circulation, and better biocompatibility of aZIF-8/5-Fu significantly improves its therapeutic efficacy in ECA-109 tumor-bearing mouse, and result in 100% survival rate over 50 days after treatment. Therefore, aZIF-8 with favorable biocompatibility and long blood circulation is expected to be a promising nano-system for efficacious cancer therapy in vivo.

源语言英语
页(从-至)740-748
页数9
期刊Bioactive Materials
6
3
DOI
出版状态已出版 - 3月 2021
已对外发布

联合国可持续发展目标

此成果有助于实现下列可持续发展目标:

  1. 可持续发展目标 3 - 良好健康与福祉
    可持续发展目标 3 良好健康与福祉

指纹

探究 'Pressure-induced amorphous zeolitic imidazole frameworks with reduced toxicity and increased tumor accumulation improves therapeutic efficacy In vivo' 的科研主题。它们共同构成独一无二的指纹。

引用此